Navigation Links
Ranbaxy Gains Tentative Approval to Manufacture and Market Valganciclovir Hydrochloride Tablets
Date:6/25/2008

'First-to-File' Status Will Provide 180-Day Marketing Exclusivity Upon

Final Approval

PRINCETON, N.J., June 25 /PRNewswire/ -- Ranbaxy Laboratories Limited (RLL), announced today that the company has received tentative approval from the U.S. Food and Drug Administration to manufacture and market Valganciclovir Hydrochloride Tablets, 450 mg. Total annual market sales for Valganciclovir HCl Tablets were $239 million (IMS - MAT: March 2008).

Ranbaxy believes that it has First-to-File status on Valganciclovir tablets, thereby providing a potential of 180-days of marketing exclusivity, offering a significant opportunity in the future.

Valganciclovir HCl Tablets are indicated for the treatment of cytomegalovirus (CMV) retinitis in patients with acquired immunodeficiency syndrome (AIDS). Valganciclovir HCl is also indicated for the prevention of cytomegalovirus (CMV) disease in kidney, heart and kidney-pancreas transplant patients at high risk (Donor CMV seropositive/Recipient CMV seronegative [(D+/R-)]).

"Ranbaxy is pleased to receive this tentative approval for Valganciclovir Hydrochloride Tablets, a medicine that has established its clinical value and utility over time. It will be launched by Ranbaxy upon receiving final approval and resolution of litigation currently pending in Federal District Court, as an affordably priced alternative to the branded product, Valcyte. This product formulation will further expand our portfolio of affordable generic alternatives and will be available to all classes of trade," said Bill Winter, Vice President of Trade Sales for RPI, USA. "This represents another potentially strong market entry for Ranbaxy medicines from among our pipeline of patent challenges, and offers us a significant future opportunity," Winter added.

Ranbaxy Pharmaceuticals Inc. (RPI) based in Jacksonville, Florida, USA, is a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), India
'/>"/>

SOURCE Ranbaxy Laboratories Limited
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Ranbaxy to Consolidate Position in Biopharmaceuticals and Speciality Injectables Including Oncology
2. Astellas and Boehringer Ingelheim Reach Settlement Agreement with Ranbaxy on Flomax Patent Case
3. Ranbaxy Receives Tentative Approval to Manufacture and Market Esomeprazole Magnesium DR Capsules
4. Ranbaxy and AstraZeneca Reach Agreement in Esomeprazole Patent Litigation
5. Shareholder Class Action Filed Against GPC Biotech AG by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP
6. FDA Approves ACAM2000(TM) Vaccine for Protection Against Smallpox
7. Former Banc of America Securities Analyst David Maris Comments on Decision by Biovail to Drop Its Claims Against Him; Denies That He is Cooperating With Biovail
8. Sangamo BioSciences Presents Data Demonstrating In Vivo Protection Against HIV Infection by CCR5-ZFN Therapeutic
9. Shareholder Class Action Filed Against LCA-Vision, Inc. by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP
10. N-Viro International Corporation Announces Dismissal of Lawsuit Against It
11. Hospitals Adopt STERIS Advanced Room Sterilization Technology in the Fight Against Superbugs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... Sept. 18, 2014 Research and ... "Global N-acetylcysteine Industry Report 2014" report ... N-acetylcysteine Industry Report 2014 is a professional and ... global N-acetylcysteine industry. The report provides ... classifications, applications and industry chain structure. The N-acetylcysteine ...
(Date:9/18/2014)... Sept. 18, 2014  U.S. biotech company Kultevat ... exclusive license for technology developed by the Donald ... in plants, including for applications in production of natural ... The technology was developed under the direction of ... and former president of the Danforth Plant Science Center, ...
(Date:9/18/2014)... Pennsylvanie, 18 septembre 2014 Mapi, ... en 1974, a été depuis 40 ans ... évaluations cliniques traditionnelles par des évaluations recentrées ... sur les impacts économiques des traitements. ... A cours d,une récente conférence ...
(Date:9/18/2014)... dysplasia is a group of rare diseases that ... cartilage. Its onset hits at the fetal stage ... in the gene encoding fibroblast growth factor receptor ... of skeletal dysplasia, thanatophoric dysplasia (TD), a skeletal ... and is often lethal, and achondroplasia (ACH), which ...
Breaking Biology Technology:Global N-acetylcysteine Industry Report 2014 2Kultevat obtains license of gene switch technology 21974 - 2014 - Mapi fĂȘte ses 40 ans 2Researchers use iPS cells to show statin effects on diseased bone 2Researchers use iPS cells to show statin effects on diseased bone 3
... their voracious appetite for wood, rendering houses to dust and ... provide the biochemical means to a greener biofuel future. ... mine of microbes that have now been tapped as a ... or waste biomass to valuable biofuels. , The ...
... will utilise technologies not currently available. An example of ... as interconnects for computer chips. This is now a ... nanotechnology researchers within the Materials Ireland Polymer Research Centre ... develop such junction structure nanotubes used various different methods ...
... us, in us and for us. Imagine them seeking out ... place. Just as a car is a combination of a ... etc, nanomachines too need to be constructed from a range ... of actuator to open and close things, to absorb shock, ...
Cached Biology Technology:DOE JGI plumbs termite guts to yield novel enzymes for better biofuel production 2DOE JGI plumbs termite guts to yield novel enzymes for better biofuel production 3DOE JGI plumbs termite guts to yield novel enzymes for better biofuel production 4DOE JGI plumbs termite guts to yield novel enzymes for better biofuel production 5Understanding of actuator properties of carbon nanotubes bring micro machines closer 2
(Date:9/17/2014)... environmental impact recently scored a major win. In August, ... bags, and Governor Jerry Brown is expected to sign ... without a fight, according to an article in ... the American Chemical Society. , Alexander Tullo, a senior ... its first small victory in 1990 when Nantucket became ...
(Date:9/17/2014)... the human retinoblastoma protein gene are a leading cause ... turned to fruit fly eyes to unlock the secrets ... paper featured on the cover of the current issue ... State University researchers provide the first detailed examination of ... the human cancer gene, said Irina Pushel, MSU undergraduate ...
(Date:9/17/2014)... crime unit designed to fight food fraud in ... being passed off as beef scientists from Germany ... describe their approach, which represents a vast improvement over ... Food Chemistry . , Hans-Ulrich Humpf and colleagues note ... But they also say that adding, for example, horse ...
Breaking Biology News(10 mins):Abnormal properties of cancer protein revealed in fly eyes 2
... Detroit automaker, it appears that nature prefers to build its ... combining advanced computational modeling and cutting-edge experiments by molecular biologists ... the most stable parts of a protein are also the ... Sept. 13 issue of the journal Structure. , Nature refuses ...
... are miniature labs that can be swallowed like a ... Their function is to screen for, detect, and ... still at a single-cell size in early development stages. ... and water. , Engineering researchers at McMaster University will ...
... the event of a large-scale smallpox bioterrorist attack in ... researchers at Fred Hutchinson Cancer Research Center that appears ... Instead, the current U.S. government policy of post-release surveillance, ... and close contacts would be sufficient to thwart an ...
Cached Biology News:Protein folding: Building a strong foundation 2Nano-devices hold promise for early-stage cancer detection 2Nano-devices hold promise for early-stage cancer detection 3Mass vaccination unnecessary in the event of a large bioterrorist US smallpox attack 2Mass vaccination unnecessary in the event of a large bioterrorist US smallpox attack 3Mass vaccination unnecessary in the event of a large bioterrorist US smallpox attack 4Mass vaccination unnecessary in the event of a large bioterrorist US smallpox attack 5
Human PDGF, CF...
... For the ultimate in utility and ... to meet the needs of the researcher. ... interior dimensions or as sheet material that ... enclosures. These isolators are autoclavable and non-cytotoxic ...
... The mycobacteria in Complete Freund's adjuvant ... injection site which enhances the immuneresponse. For ... used for the initial injections; Incomplete Freund's ... Antigens (preferably in saline) are typically mixed ...
The ELISA Kit for Hepatitis B Surface Antigen (HBsAg) is an in vitro enzyme immunoassay for the detection of HBsAg in human serum or plasma....
Biology Products: